65th ASH Annual Meeting & Exposition: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterizing Response and Resistance to CAR-T and TCEs

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Oral and Poster Abstracts
Oral

Research, Translational Research

Harbor Ballroom (Manchester Grand Hyatt San Diego)

Moderators:

Faith E. Davies, MD, Myeloma Research Program, NYU Langone, Perlmutter Cancer Center and Johannes M Waldschmidt, MD, University of Wuerzburg Medical Center

Disclosures:

Waldschmidt: Janssen: Consultancy; Sanofi: Consultancy; Oncopeptides: Consultancy; Takeda: Consultancy; Pfizer: Consultancy; Bristol Myers Squibb: Research Funding; Pharmamar: Consultancy; Skyline Diagnostics: Consultancy, Research Funding; abc biopply: Consultancy.

Novel exploration of the tumor and iTME response to CAR-T and T cell engangers.

9:30 AM

451

Secondary Genetic Events Impact the Expression of Key Immunotargets on the Surface of Multiple Myeloma Cells

Umair Munawar¹^*, Patrick Eiring, PhD²^*, Cornelia Vogt³^*, Larissa Haertle, PhD^3,4^*, Seungbin Han³^*, Silvia Nerreter³^*, Eva Teufel³^*, Max Steinhardt³^*, Xiang Zhou³^*, Santiago Barrio, PhD^4,5^*, Hermann Einsele, MD, PhD⁶^*, Johannes M Waldschmidt, MD⁷, Leo Rasche, MD⁶^*, Markus Sauer, PhD²^* and K. Martin Kortüm, MD³^*

¹Department of Internal Medicine II, University Hospital of Wuerzburg, Wuerzburg, Germany
²Department of Biotechnology and Biophysics, University of Würzburg, Würzburg, Germany
³Department of Internal Medicine II, University Hospital Wuerzburg, Wuerzburg, Germany
⁴Department of Hematology, Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center (CNIO), Complutense University Madrid, Madrid, Spain
⁵Altum Sequencing Co., Madrid, Spain
⁶Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
⁷Department of Internal Medicine II, University of Wuerzburg Medical Center, Wuerzburg, Germany

9:45 AM

452

The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting CST6 Against Multiple Myeloma and Suppresses Osteolytic Lesions

Fumou Sun¹^*, Yan Cheng, PhD¹^*, Jin-Ran Chen, PhD²^*, Visanu Wanchai, PhD³^*, David E. Mery, PhD³, Hongwei Xu, DDS¹^*, Dongzheng Gai, MD, PhD¹^*, Samer Al Hadidi, MD, MSc⁴, Carolina Schinke, MD⁴, Sharmilan Thanendrarajan, MD⁴^*, Maurizio Zangari, MD⁴, Frits van Rhee, MD, PhD⁴, John D Shaughnessy, Jr, PhD³^*, Guido Tricot, MD³^* and Fenghuang Zhan, MD, PhD⁴

¹Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical, Little Rock, AR
²Arkansas Children’s Nutrition Center,, University of Arkansas For Medical Sciences, Little Rock, AR
³Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas For Medical Sciences, Little Rock, AR
⁴Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR

10:00 AM

453

Single Cell Multi-Omic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma

Maximilian Merz, MD¹, Luise Fischer²^*, Jaren Sia³^*, Patrick Born⁴^*, Ronald Weiss⁵^*, Nora Grieb¹^*, Michael Rade⁶^*, Andreas Boldt⁷^*, Stephan Fricke⁸^*, Paul Franz⁹^*, Jonathan Scolnick, PhD¹⁰^*, Lakshmi Venkatraman³^*, Stacy Xu, PhD¹¹^*, Christina Kloetzer¹²^*, Simone Heyn¹²^*, Anne Sophie Kubasch, MD¹³^*, Ronny Baber¹⁴^*, Song Yau Wang⁵^*, Enrica Bach¹²^*, Sandra Hoffmann¹²^*, Jule Ussmann⁴^*, Klaus H Metzeler, MD¹⁵, Marco Herling¹²^*, Carmen Herling, MD¹²^*, Madlen Jentzsch¹²^*, Georg-Nikolaus Franke¹²^*, Ulrich Sack⁷^*, Ulrike Koehl¹⁶^*, Kristin Reiche⁶^*, Uwe Platzbecker, MD¹⁷ and Vladan Vucinic, M.D.¹⁸^*

¹Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany
²University of Leipzig, Leipzig, Saxony, Germany
³Singleron Biotechnologies, Singapore, Singapore
⁴Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany
⁵University of Leipzig, Leipzig, Germany
⁶Fraunhofer IZI, Leipzig, Germany
⁷University of Leipzig, Leipzig, DEU
⁸Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany
⁹Fraunhofer IZI, Leipzig, DEU
¹⁰Singleron Biothechnologies Pte Ltd, Singapore, Singapore
¹¹Singleron Biotechnologies Pte LtD, Singapore, Singapore
¹²Department of Hematology, Celltherapy, Hemostaseology and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany
¹³Department of Hematology, University Hospital of Leipzig, Dresden, Germany
¹⁴Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig Medical Center, Leipzig, Germany
¹⁵Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University Leipzig Medical Center, Leipzig, NA, Germany
¹⁶Fraunhofer IZI, Leipzig, Saxony, DEU
¹⁷Department of Hematology, University Hospital of Leipzig, Leipzig, Germany
¹⁸Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University of Leipzig, Leipzig, Germany

10:15 AM

454

Bclxl Prevents Progressive Exhaustion in BCMA CAR T Cells with Maintenance of High TCF1 Expressing T Cells

Mansour Poorebrahim, PhD¹^*, Holly Lee, MD²^*, Sacha Benaoudia³^*, Ranjan Maity, PhD²^*, Sungwoo Ahn, PhD²^*, Noemie Leblay, PhD¹^*, Elie Barakat²^*, Remi Tilmont, MD²^*, Douglas Mahoney³^*, Lawrence H. Boise⁴, Paola Neri, MD, PhD¹ and Nizar J Bahlis, MD¹

¹Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
²Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
³Department of Microbiology, University of Calgary, Calgary, Canada
⁴Winship Cancer Institute of Emory University, Atlanta

10:30 AM

455

Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma

Deeksha Vishwamitra, PhD¹, Sheri Skerget¹^*, Diana Cortes, PhD¹^*, Tatiana Perova¹^*, Onsay Lau¹^*, Cuc Davis¹^*, Yue Guo, PhD¹^*, Xin Miao¹^*, Tara Stephenson, PhD¹^*, Caroline Hodin²^*, Clarissa Uhlar¹^*, Danielle Trancucci³^*, Katherine Chastain, MD³, Nizar J Bahlis, MD⁴, Niels W.C.J. Van De Donk⁵^* and Raluca Verona, PhD¹

¹Janssen Research & Development, Spring House, PA
²Janssen Research & Development BE, Antwerp, Belgium
³Janssen Research & Development, Raritan, NJ
⁴Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
⁵Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands

10:45 AM

456

Characterization of JNJ-79635322, a Novel BCMAxGPRC5DxCD3 T-Cell Redirecting Trispecific Antibody, for the Treatment of Multiple Myeloma

Ram Pillarisetti, MSc¹^*, Danlin Yang²^*, Jianhong Yao, MS²^*, Melissa Smith²^*, Leopoldo Luistro, PhD³^*, Peter Vulfson²^*, James Testa Jr.²^*, Kathryn Packman, PhD⁴^*, Scott Brodeur²^*, Ricardo M. Attar, PhD⁵^*, Yusri Elsayed, MD, MMSc, PhD³ and Ulrike Philippar, PhD⁶

¹Janssen Pharamaceuticals, Spring House, PA
²Janssen Research & Development, Spring House, PA
³Janssen Research & Development, LLC, Spring House, PA
⁴Janssen Research & Development, LLC, Cambridge, MA
⁵Janssen Research and Development, Spring House, PA
⁶Janssen Research & Development, LLC, Beerse, Belgium

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

651.O3.6 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterizing Response and Resistance to CAR-T and TCEs